The Healthy Heroes Study

August 3, 2021 updated by: Pam Taub, MD, University of California, San Diego

Optimizing Circadian Rhythms by Regulating Eating Patterns to Reduce Cardiometabolic Disease Risk Among Firefighters--The Healthy Heroes Study

This is the first study of its kind to assess and test an intervention to improve biological rhythms and general health of shift workers, specifically first responders with San Diego Fire and Rescue. In a randomized control trial, investigators intend to measure the health impact of Time Restricted Eating in emergency responders who work a 24-hour shift schedule.

Study Overview

Detailed Description

Participants will be randomly assigned to a control group of behavioral nutrition counseling (standard of care) or the intervention group of standard of care with the addition of adopting a 10 hour eating window for one year (TRE). For the first 3 months of intervention, participants will be monitored closely by the research team. For the following 9 months, participants will be in a self-monitored intervention period. Investigators will evaluate the impact of TRE on blood glucose levels, biomarkers, sleep/mood, and weight loss. These assessments will be made at baseline, at the end of the 12-week monitored intervention period, and every 3 months (months 6, 9, and 12) during the self-monitored intervention period for one year. Food/drink intake, activity, and sleep will be monitored with the smartphone myCircadianClock application ("mCC app") throughout the study. A continuous glucose monitor, a wrist-worn actigraphy device, and questionnaires will also be used during the study.

Study Type

Interventional

Enrollment (Actual)

153

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • La Jolla, California, United States, 92093
        • University of California, San Diego

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

As per recommendations from the fire department, fire department unions, and funding agencies, we did not require compromised health measures (e.g. hyperglycemia, hypertension, etc.) as inclusion criteria for they would be discriminatory against some firefighters.

Inclusion Criteria:

  • Firefighter or work a 24-hr shift schedule with San Diego Fire and Rescue
  • Age: 21-65 years
  • Own a smartphone (Apple or Android Operating System)
  • If participants are on cardiovascular medications (HMG-CoA reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period

Exclusion Criteria:

  • Insulin-dependent diabetes mellitus
  • Presence of acute chronic inflammatory or autoimmune disease (defined by acute symptoms or C-reactive protein >10 mg/L), malabsorption syndromes, liver disease, or kidney disease (stage 3 or greater)
  • Uncontrolled thyroid disease
  • Intake of drugs likely to interfere with study endpoints, including corticosteroids, anabolic steroids, anti-psychotics, antiretroviral drugs, and immunosuppressive drugs (within 3 months of starting the study)
  • Presence or recent history of anemia (hematocrit <33% within 3 months of starting the study)
  • History of bariatric surgery
  • Pregnant or breast-feeding women
  • Current or recent (within 12 months of starting the study) pregnancy or breastfeeding, or intention of becoming pregnant in the next 6 months
  • Any cancer other than non-melanoma skin cancer in the last 3 years
  • On a special or prescribed diet for other reasons (e.g. Celiac disease)
  • Depression determined by the Beck Depression Inventory (BDI)
  • Planned international travel during study period
  • Insufficient logging on the mCC app (does not log at least 2 entries a day for 10 of 14 days) during baseline will exclude from being randomized into the intervention period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: TRE + SOC
Time Restricted Eating + Standard of Care
Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
Other Names:
  • Time Restricted Eating
OTHER: SOC
Standard of Care
Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the impact of TRE on glucose homeostasis at end of intervention compared to baseline
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Measured by an ambulatory continuous glucose monitoring device and blood work throughout the study.

Note: Significant changes expected in participants who had elevated glucose homeostasis at baseline. No significant changes expected in those within normal ranges at baseline. Primary endpoint analysis will be done by comparing baseline and 12-week intervention.

primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Assess the feasibility and adherence of TRE
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Measured by percentage of days logged that participants ate within their 10-hour window and by end of study responses.

Note: Significant changes expected in participants in the TRE arm of the study on and off shift. No significant changes expected in the standard of care arm of the study. Primary endpoint analysis will be done by comparing baseline and 12-week intervention.

primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess changes in metabolic biomarkers in response to TRE at end of intervention compared to baseline
Time Frame: Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Measured with blood biochemistry.Measured with blood biochemistry under TRE, including, but not limited to: fasting glucose, HbA1c, cholesterol, and triglycerides.

Note: Significant changes expected in participants who had abnormal levels at baseline (e.g. elevated LDL cholesterol, low HDL cholesterol, elevated triglycerides). No significant changes expected in those were within normal ranges at baseline.

Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Systolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline
Time Frame: Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured at baseline and during TRE intervention. Note: Significant changes expected in participants who had elevated systolic blood pressure at baseline. No significant changes expected in those without elevated systolic blood pressure at baseline.
Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Diastolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured at baseline and during TRE intervention. Note: Significant changes expected in participants who had elevated diastolic blood pressure at baseline. No significant changes expected in those without elevated diastolic blood pressure at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Body weight (kg)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured on a digital scale. Note: Significant changes expected in participants who had elevated weight at baseline. No significant changes expected in those who were not overweight at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass index (kg/m^2)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Calculated from body weight (kg) and height (m). Note: Significant changes expected in participants who had elevated BMI at baseline. No significant changes expected in those whose BMI was not elevated at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Waist and hip circumference (cm)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured with standardized body tape measure. Note: Significant changes expected in participants who had increased waist and hip circumference at baseline. No significant changes expected in those without increased waist and hip circumference at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Hip (cm)/waist (cm) ratio
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured using tape measure. Note: Significant changes expected in participants who had an increased hip/waist ratio at baseline. No significant changes expected in those without increases at baseline
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Body composition including but not limited to fat percentage (%), fat mass (kg), and lean mass (kg)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured by Tanita Digital Scale. Note: Significant changes expected in participants who had elevations levels at baseline. No significant changes expected in those without elevations at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Questionnaires (quality of life, sleep, and health)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Measured by SF-36, PSQI, and ESS. Note: Significant changes expected in participants who had decreased self-reporting of the above-mentioned questionnaires at baseline. No significant changes expected in those without decreases at baseline.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 8, 2018

Primary Completion (ACTUAL)

March 4, 2021

Study Completion (ACTUAL)

March 4, 2021

Study Registration Dates

First Submitted

April 19, 2018

First Submitted That Met QC Criteria

May 9, 2018

First Posted (ACTUAL)

May 22, 2018

Study Record Updates

Last Update Posted (ACTUAL)

August 4, 2021

Last Update Submitted That Met QC Criteria

August 3, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fasting

Clinical Trials on Time Restricted Eating + Standard of Care

3
Subscribe